This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I35 (Nonrheumatic aortic valve disorders) | Special Copayment Reduction: V192 (heart disease special copayment reduction: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Degenerative aortic valve disease, calcific aortic stenosis, noninfective aortic valve insufficiency, Calcific aortic valve disease (CAVD), Degenerative aortic stenosis |
| C. Adult onset | Presents mainly as degenerative change after age 60, and severe aortic stenosis is observed in about 3–4% of people aged 75 or older. Valve stenosis and insufficiency occur alone or in combination. |
| 1. History | History of progress from Mönckeberg's description of calcification in the 19th century to surgical replacement in the 20th century and transcatheter aortic valve replacement (TAVR) in the 21st century |
| 2. Causes | Various nonrheumatic causes, including degenerative calcification, congenital bicuspid valve, previous infective endocarditis, and radiation injury |
| 3. Genetics | NOTCH1, LDLR, LPA mutations and increased risk of calcification; genetic basis of bicuspid aortic valve |
| 4. General epidemiology | 2–3% of people aged 65 or older, severe disease in 3–4% of those aged 75 or older; in Europe and North America, degenerative causes predominate at about 82% |
| 5. Pathophysiology | An active process of endothelial injury → lipid deposition → inflammatory cell infiltration → myofibroblast differentiation → osteoblastic calcification |
| 6. Symptoms | Angina, syncope, exertional dyspnea; with insufficiency, orthopnea, paroxysmal nocturnal dyspnea, increased pulse pressure |
| 7. Signs | Systolic ejection murmur, sustained apical impulse, loss of aortic valve opening sound; with insufficiency, high-pitched diastolic murmur and water-hammer murmur |
| 8. Screening | Echocardiography if auscultation is abnormal; regular echocardiographic monitoring in older adults; follow-up of patients with bicuspid aortic valve |
| 9. Diagnosis | Transthoracic and transesophageal echocardiography, CT calcium score (Agatston score), cardiac catheterization, cardiac MRI |
| 10. Treatment | Surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), balloon valvuloplasty; drugs are used to relieve heart failure symptoms |
| 11. Prognosis | Without treatment after symptom onset, 50% die within 2–3 years; 5-year survival after TAVR/SAVR is 80% or higher |
| 12. Prevention | Management of atherosclerotic risk factors (hypertension, dyslipidemia, diabetes, smoking cessation); early registration and follow-up of patients with bicuspid valves |
| 13. References | Nishimura RA et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease … and 9 other papers |
Historical descriptions of nonrheumatic aortic valve disorders date back to the late 19th century. In 1904 the German pathologist Johann Georg Mönckeberg histologically described calcified lesions of the aortic valve observed in elderly patients and classified them as an independent degenerative process distinct from atherosclerosis. At the time, however, the disease was regarded simply as a result of aging and was not recognized as a clinically treatable disease.
In the mid-20th century, as surgical techniques advanced, a surgical approach to aortic valve disease became possible. In 1960 Harken and Starr each successfully performed surgical aortic valve replacement (SAVR) using mechanical valves, fundamentally shifting the treatment paradigm for this disease. Subsequently, the development of tissue valves combined with advances in cardiopulmonary bypass technology greatly improved surgical success rates.
In the 1980s, with the spread of echocardiography, noninvasive quantitative assessment became routine, and a system for grading the severity of aortic stenosis by valve area, mean pressure gradient, and peak flow velocity was established. In particular, the application of the continuity equation by Hatle and Angelsen in 1985 made accurate valve area calculation possible.
In 2002 Alain Cribier performed the world's first successful transcatheter aortic valve replacement (TAVR) in a human. This groundbreaking procedure provided a new treatment option for elderly patients for whom conventional surgery was considered high risk. Subsequently, through the PARTNER trials (2010–2011), TAVR became standard treatment in inoperable or high-surgical-risk patients, and its indications were later expanded to intermediate- and low-risk patients.
The ACC/AHA valvular heart disease guidelines published in 2014 and 2021 established modern diagnostic and treatment standards for nonrheumatic aortic valve disorders, emphasizing an evidence-based approach particularly to symptom onset and the timing of surgery. Today TAVR has become a procedure performed hundreds of thousands of times or more annually worldwide, and device innovation and clinical trials continue.
Nonrheumatic aortic valve disorders arise from various causes other than valve damage due to rheumatic fever. The most common cause is degenerative calcification (calcific/degenerative aortic valve disease), in which chronic hemodynamic stress and oxidative damage associated with aging cause lipid deposition and calcification in the valve leaflets. This process is an active inflammatory process similar to atherosclerosis, and risk factors such as hypertension, dyslipidemia, diabetes, and smoking are involved.
Congenital bicuspid aortic valve (BAV) is one of the important causes of nonrheumatic aortic valve disorders and occurs in about 1–2% of the general population. Because of structural vulnerability and abnormal flow patterns compared with a tricuspid valve, a bicuspid valve tends to cause stenosis or insufficiency at a much younger age (40s–60s). About 50% of patients with BAV eventually require aortic valve surgery.
Damage after infective endocarditis can cause aortic insufficiency or stenosis through destruction of valve tissue and scar formation. In addition, radiation therapy can cause aortic stenosis by inducing valve fibrosis and calcification, particularly in patients who received mediastinal radiation, and the latency period can be as long as several decades.
Aortic annular dilation due to aortic dissection or aortic aneurysm is an important cause of pure aortic insufficiency. This mechanism is prominent in connective tissue disorders such as Marfan syndrome and Loeys-Dietz syndrome. Traumatic valve injury and drug-induced valve changes (e.g., the appetite suppressant fenfluramine) are also rare causes.
The genetic basis of nonrheumatic aortic valve disorders is becoming increasingly clear through recent research. Loss-of-function mutations in the NOTCH1 gene are strongly associated with the development of bicuspid aortic valve and with aortic valve calcification in adults. The NOTCH1 signaling pathway plays an essential role in valve formation, and abnormalities in this pathway are known to promote aortic valve calcification.
Genetic factors in bicuspid aortic valve (BAV) are also important. BAV tends to be inherited in an autosomal dominant pattern, and mutations in transcription factor genes such as GATA5, GATA6, NKX2-5, and KCNJ2 are associated with some familial BAV. When there is a family history, screening echocardiography of first-degree relatives is recommended.
Genome-wide association studies (GWAS) have reported that gene loci such as LPA (lipoprotein(a)), LDLR, PALMD, TEX41, and IL6 are significantly associated with the risk of calcific aortic valve disease. In particular, elevated Lp(a) levels are an independent risk factor for aortic valve calcification, and the rs10455872 and rs3798220 polymorphisms of the LPA gene are related to this. Therapies targeting Lp(a) reduction are currently in clinical trials, and genetic risk stratification is expected to play an important role in future prevention strategies.
When taking a family history, it is important to identify a family history of ascending aortic aneurysm and aortic dissection in addition to aortic valve disease. Especially in patients with bicuspid valves, aortic dilation is commonly present, so aortic imaging follow-up should also be performed.
Nonrheumatic aortic valve disorders are the most common valvular heart disease in developed countries. According to the European Society of Cardiology's Euro Heart Survey, degenerative/calcific causes account for about 81.9% of the causes of aortic stenosis, while rheumatic causes account for only 11.2% and congenital causes 5.6%. This is the combined result of successful prevention of rheumatic fever and population aging.
Prevalence is closely related to age. In adults aged 65 or older, the prevalence of aortic sclerosis is estimated at about 25% and of stenosis at about 2–3%, and in those aged 75 or older the prevalence of severe aortic stenosis reaches 3–4%. In a Swedish study, the median age at onset of calcific aortic stenosis was 68 years, and men accounted for 66%.
The prevalence of aortic insufficiency is lower than that of stenosis, but mild or greater insufficiency is observed in about 10% of the general population. Overall, aortic stenosis is more common in men, and the proportion of insufficiency is relatively higher in women. Korean health insurance data also show a continuously increasing number of surgeries for aortic valve disease in people aged 65 or older, and the number of TAVR procedures has increased every year since coverage by National Health Insurance began in 2016.
Worldwide, the absolute burden of aortic stenosis is expected to continue increasing with population aging. In developing countries, rheumatic causes still account for a considerable proportion, but with economic development and improved standards of medical care, a trend toward an increasing proportion of nonrheumatic causes is observed.
Nonrheumatic aortic valve disorders, especially calcific aortic valve disease, arise not simply as a result of aging but through an active pathological process. This process is a complex cascade that begins with early stages similar to atherosclerosis and ultimately culminates in calcification resembling osteogenesis.
Initially, endothelial injury and lipid (LDL, oxidized LDL) deposition occur in the fibrosa layer of the valve leaflets. In response, macrophages and T lymphocytes infiltrate, and inflammatory cytokines (IL-1β, TNF-α, TGF-β) are secreted, triggering a local inflammatory response. In this process, valvular interstitial cells (VICs) differentiate into myofibroblasts, and extracellular matrix remodeling occurs.
As the lesion progresses, VICs show differentiation into an osteoblast-like phenotype, with increased expression of osteogenic transcription factors such as Runx2 and Osterix. Along with this, activation of the BMP (Bone Morphogenetic Protein) signaling pathway, increased alkaline phosphatase, and deposition of calcium phosphate crystals proceed sequentially, forming calcific nodules on the valve.
In aortic insufficiency, in addition to lesions of the valve itself, aortic annular dilation and aortic root dilation are major mechanisms. When the annulus dilates due to connective tissue disorders, aortic hypertension, or aortitis, even normal valve leaflets cannot achieve adequate coaptation, and regurgitation occurs. Chronic severe aortic insufficiency causes left ventricular volume overload, leading to eccentric left ventricular hypertrophy and left ventricular dilation, and in the long term to reduced left ventricular systolic function.
Nonrheumatic aortic stenosis presents with symptoms after a long asymptomatic latent period. The classic symptom triad (SAD triad) consists of angina, syncope, and heart failure symptoms (dyspnea). Angina results from an imbalance between increased oxygen demand of the hypertrophied left ventricle and reduced coronary blood flow, and can occur even without concomitant coronary artery disease. Syncope occurs mainly during exercise and is caused by reduced cerebral perfusion due to vasodilation in a state of fixed cardiac output. Dyspnea is a symptom of heart failure that begins with left ventricular diastolic dysfunction and progresses to reduced systolic function, worsening from exertional dyspnea to orthopnea and paroxysmal nocturnal dyspnea.
In aortic insufficiency, palpitations (a sensation of increased heartbeat) and a sensation of pulsation in the neck may be prominent early on. As the disease progresses to severe, discomfort due to left ventricular dilation, reduced exercise tolerance, and paroxysmal nocturnal dyspnea appear. Acute aortic insufficiency (e.g., due to endocarditis or aortic dissection) can cause a serious emergency accompanied by pulmonary edema and cardiogenic shock.
Until symptoms develop, patients often have no particular difficulty in daily life, so early detection through regular auscultation and echocardiography is important. In some patients, atrial fibrillation, thromboembolism, or sudden death may be the first clinical manifestation, so caution is needed.
The representative physical examination finding of aortic stenosis is a systolic ejection murmur. This murmur is best heard at the right upper sternal border (aortic auscultation area) and is a harsh, diamond-shaped murmur radiating to the neck. The more severe the stenosis, the more the peak of the murmur tends to shift to late systole. At the same time, paradoxical splitting of S2 or a single A2 sound (loss of A2) may be observed, and an S4 gallop due to left ventricular hypertrophy is also commonly heard. In severe stenosis, reduced pulse pressure and a slow, weak pulse (pulsus parvus et tardus) are characteristic.
Physical examination in aortic insufficiency shows a wide variety of signs. A high-pitched, blowing decrescendo diastolic murmur is heard at the left lower sternal border. An Austin Flint murmur (a functional mitral stenosis murmur at the leaflets) may be heard at the apex. Signs of widened pulse pressure throughout the body may include Corrigan pulse (water-hammer pulse), Quincke sign (capillary pulsation), de Musset sign (head bobbing), Traube sign (pistol-shot sounds over the femoral artery), and Duroziez sign (double murmur over the femoral artery). Lateral displacement of the apical impulse and a hyperdynamic impulse due to left ventricular hypertrophy are observed.
Screening for nonrheumatic aortic valve disorders mainly begins with clinical auscultation. When a systolic ejection murmur or diastolic murmur is heard, performing echocardiography is the standard approach. However, in older adults the loudness of the murmur does not necessarily correspond to the severity of stenosis, so caution is needed.
In high-risk groups (age 75 or older, patients with bicuspid aortic valve, people with multiple cardiovascular risk factors), regular transthoracic echocardiography is recommended even without symptoms. Patients with bicuspid aortic valve need follow-up echocardiography every 1–5 years after initial diagnosis, depending on age and rate of valve change. When aortic stenosis is confirmed, follow-up testing is recommended at intervals according to severity: mild (5 years), moderate (1–2 years), and severe (6–12 months).
In patients with known aortic stenosis, exercise stress testing can be used to assess whether symptoms have developed. In patients with asymptomatic severe aortic stenosis, exercise testing uncovers latent symptoms and provides useful information for deciding the timing of surgery. However, exercise stress testing is contraindicated in patients with symptomatic severe stenosis.
Transthoracic echocardiography (TTE) is central to the diagnosis of nonrheumatic aortic valve disorders. 2D imaging confirms valve morphology (calcification, number of cusps) and restricted leaflet motion, and Doppler is used to measure peak flow velocity (Vmax), mean pressure gradient, and aortic valve area (AVA) calculated by the continuity equation. The criteria for severe stenosis are Vmax ≥4 m/s, mean pressure gradient ≥40 mmHg, and AVA ≤1.0 cm². For the paradoxical low-flow, low-gradient variant, dobutamine stress echocardiography is useful in determining whether true severe stenosis is present.
Transesophageal echocardiography (TEE) is performed when evaluation of valve morphology and function by TTE is insufficient. It is especially important for anatomical assessment of the valve before TAVR, aortic valve sizing, and identifying the mechanism of aortic regurgitation. CT (cardiac computed tomography) is essential for measuring the valve calcium score (Agatston score) and for TAVR procedure planning (assessment of annulus size, coronary artery height, and access route). The aortic valve calcium score helps predict stenosis severity and prognosis independently of Vmax.
Cardiac MRI is used to quantify regurgitant volume and regurgitant fraction in aortic insufficiency and to evaluate left ventricular function. It contributes to deciding the timing of surgery by accurately identifying thresholds of left ventricular dilation and reduced systolic function. Cardiac catheterization is performed when there is discordance in severity on noninvasive tests or when simultaneous coronary artery evaluation is needed.
The definitive treatment of nonrheumatic aortic valve disorders is mechanical correction of the valve. Surgical aortic valve replacement (SAVR) is the standard treatment for patients with intermediate or higher surgical risk, and a mechanical or tissue valve is chosen considering the patient's age, suitability for anticoagulation, durability, and other factors. Mechanical valves have excellent durability but require lifelong warfarin anticoagulation, while tissue valves do not require anticoagulation but may develop structural valve deterioration (SVD) after 10–15 years.
Transcatheter aortic valve replacement (TAVR) began in patients at high surgical risk or inoperable patients, and its indications have now expanded to patients at low surgical risk. In the PARTNER 3 and Evolut Low Risk trials, TAVR showed noninferior or superior clinical outcomes compared with surgery in low-risk patients. The major complications of TAVR include vascular injury, paravalvular leakage, the need for permanent pacemaker implantation, and stroke.
Emergency surgery is required for acute or subacute aortic insufficiency. In chronic aortic insufficiency, surgery is recommended when symptoms develop, or even when asymptomatic, when the left ventricular end-systolic diameter is ≥50 mm or the left ventricular ejection fraction (LVEF) is <55–60%. Aortic valve repair may be attempted at experienced centers, particularly in patients with bicuspid valves in whom insufficiency is the predominant form. As for medical treatment, there is currently no drug proven to slow the progression of stenosis, and statins are not recommended because of negative clinical trial results. Comorbidities such as heart failure and hypertension are actively managed.
Nonrheumatic aortic stenosis has a relatively favorable course in the asymptomatic phase, but the natural course after symptom onset is poor. The mean survival is reported to be about 5 years after onset of angina, 3 years after syncope, and 1–2 years after heart failure. After symptom onset, the annual risk of sudden death reaches about 15–20%. Even in asymptomatic severe aortic stenosis, there is a risk of sudden death of about 1–2% per year, and the rate of symptom onset within 5 years is 40–60%.
Prognosis improves markedly after timely valve replacement. Five-year survival after TAVR or SAVR varies with baseline risk but reaches over 80% in low-risk patients. Recovery of left ventricular function after surgery is determined by preoperative LVEF and the degree of left ventricular hypertrophy, and LVEF tends to recover in patients operated on at the appropriate time. In aortic insufficiency, undergoing surgery before the left ventricle becomes irreversibly dilated or systolic function is severely reduced is the key determinant of prognosis. Regular echocardiographic follow-up and prosthetic valve function monitoring are needed even after surgery.
To date, no drug therapy has been proven to directly inhibit the progression of calcific aortic valve disease, but management of atherosclerotic risk factors is the key preventive strategy. Aggressive control of hypertension, management of dyslipidemia (especially LDL cholesterol and Lp(a)), glycemic control in diabetes, and smoking cessation are recommended. Although the effect of statins in inhibiting valve calcification has not been proven in randomized clinical trials, continued prescription is recommended to prevent concomitant atherosclerotic disease.
For patients with bicuspid aortic valve (BAV), regular follow-up after early diagnosis is very important. When there is a family history of BAV, echocardiographic screening of first-degree family members is recommended. Patients with BAV should maintain proper oral hygiene to prevent infective endocarditis and should check whether antibiotic prophylaxis is indicated before invasive procedures. In addition, considering the long-term possibility of aneurysm development, aortic imaging follow-up should also be performed.
In patients with aortic insufficiency, afterload reduction with vasodilators (mainly angiotensin-converting enzyme inhibitors or nifedipine) may help with left ventricular dilation and delay the timing of surgery in some patients, but the level of evidence for this is limited, and it does not replace surgery. Prophylactic use of beta-blockers or angiotensin receptor blockers in asymptomatic severe aortic insufficiency is currently not clearly recommended.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2014;63(22):e57-e185. DOI: 10.1016/j.jacc.2014.02.536. PMID: 24603191.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143(5):e72-e227. DOI: 10.1161/CIR.0000000000000923. PMID: 33332150.
Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process. Circulation. 2011;124(16):1783-1791. DOI: 10.1161/CIRCULATIONAHA.110.006767. PMID: 22007101.
Mack MJ, Leon MB, Thourani VH, et al. (PARTNER 3 Investigators). Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. New England Journal of Medicine. 2019;380(18):1695-1705. DOI: 10.1056/NEJMoa1814052. PMID: 30883058.
Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging. 2013;14(7):611-644. DOI: 10.1093/ehjci/jet105. PMID: 23733442.
Thanassoulis G, Campbell CY, Owens DS, et al. Genetic Associations with Valvular Calcification and Aortic Stenosis. New England Journal of Medicine. 2013;368(6):503-512. DOI: 10.1056/NEJMoa1109034. PMID: 23388002.
Coffey S, Roberts-Thomson R, Brown A, et al. Global epidemiology of valvular heart disease. Nature Reviews Cardiology. 2021;18(12):853-864. DOI: 10.1038/s41569-021-00570-z. PMID: 34172950.
Simard L, Côté N, Dagenais F, et al. Sex-Related Discordance Between Aortic Valve Calcification and Hemodynamic Severity of Aortic Stenosis. Circulation Research. 2017;120(4):681-691. DOI: 10.1161/CIRCRESAHA.116.309306. PMID: 27932472.
Mahjoub H, Mathieu P, Voisine P, et al. Determinants of progression of aortic stenosis: Is there an effect of statin therapy? Journal of the American College of Cardiology. 2014;63(4):306-314. DOI: 10.1016/j.jacc.2013.09.051. PMID: 24184249.
Tribouilloy C, Rusinaru D, Bohbot Y, et al. Natural history and outcomes of asymptomatic severe aortic regurgitation in the contemporary era. Heart. 2021;107(8):638-644. DOI: 10.1136/heartjnl-2020-317342. PMID: 33037022.